Abstract Number: 1731 • 2012 ACR/ARHP Annual Meeting
IgA Anti-β2glycoprotein I Antibodies Are Pathogenic in a Mouse Model of APS
Background/Purpose: Recently exclusive IgA anti-b2Glycoprotein I (ab2GPI) seropositivity - in the absence of any other antiphospholipid (aPL) antibodies- has been reported particularly in SLE patients. …Abstract Number: 1732 • 2012 ACR/ARHP Annual Meeting
Annexin A5 Resistance Identifies a Subset of Thrombosis Patients in Systemic Lupus Erythematosus
Background/Purpose: Annexins are a family of structurally related proteins that bind to phospholipids in a calcium dependant manner. Annexin A5 (AnxA5), present on the surfaces…Abstract Number: 1733 • 2012 ACR/ARHP Annual Meeting
Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results of an Ongoing Prospective Study
Background/Purpose: One proposed mechanism of aPL-mediated thrombosis is disruption of the AnxA5 shield, allowing initiation of coagulation reactions on phospholipid surfaces. The AnxA5-RA measures the…Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting
Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…Abstract Number: 1735 • 2012 ACR/ARHP Annual Meeting
Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)
Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing…Abstract Number: 1736 • 2012 ACR/ARHP Annual Meeting
The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network created to conduct well-designed clinical trials in persistently…Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…Abstract Number: 1698 • 2012 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologics in 2,281 US Patients with Rheumatoid Arthritis
Background/Purpose: Identifying predictors of discontinuation of biologic treatment for Rheumatoid Arthritis (RA) has clinical and research importance given the chronicity of RA and high costs…Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting
Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry
Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…Abstract Number: 1700 • 2012 ACR/ARHP Annual Meeting
Prevalence of Spondyloarthritis in Anterior Uveitis Patients: The Sentinel Study
Background/Purpose: Anterior uveitis (AU) is the most common form of uveitis in western countries with an annual incidence rate of about eight new cases for…Abstract Number: 1701 • 2012 ACR/ARHP Annual Meeting
Validation of the New ASAS Criteria for Classification of Early Spondyloarthritis in the Esperanza Cohort
Background/Purpose: To validate the new axial and peripheral ASAS criteria in patients with early spondyloarthritis (SpA) and the full spectrum of clinical manifestations under clinical…Abstract Number: 1702 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that might be due to the chronic underlying inflammatory process. It is still…Abstract Number: 1703 • 2012 ACR/ARHP Annual Meeting
Relationship Between Tobacco Smoking and Radiographic Spinal Progression in Axial Spondyloarthritis: The Role of Inflammatory Activity
Background/Purpose: Cigarette smoking is associated with functional impairment [1, 2] and radiographic severity of ankylosing spondylitis (AS) [3, 4]. Moreover, smoking status at baseline was…Abstract Number: 1704 • 2012 ACR/ARHP Annual Meeting
New Threshold Values for Spinal Mobility Measures Based On a Large Nationally Representative Sample of U.S. Adults Ages 20-69 Years
Background/Purpose: Spinal mobility measures are widely utilized for diagnosis and assessment of disease severity in patients with Ankylosing Spondylitis. The previously proposed threshold values for…Abstract Number: 1705 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) and is defined by the ASAS criteria.1 It is characterized by bone…